Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, pharmacokinetics, and pharmacodynamics of CSL312 in idiopathic pulmonary fibrosis
2021-003162-12Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing CSL312 with Placebo (2 arms). Primary endpoint: Treatment-emergent serious adverse events. Started Nov 2021; status: completed.
02
Drugs
garadacimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2021-003162-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003162-12.